Related Experiment Video
Updated: Jun 7, 2025
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
[Activity of sacituzumab govitecan in skin metastases: description of a case.]
1Medical Oncology, Breast & GYN Unit, Irccs Istituto romagnolo per lo studio dei tumori (Irst) "Dino Amadori", Meldola (Forlì-Cesena).
Abstract:
Advanced triple-negative breast cancer is characterized by a severe prognosis, poor response to conventional therapies and poses multiple challenges for the medical oncologist. However, recent developments in molecular research and targeted therapy are opening up new perspectives with encouraging results for the treatment of this aggressive disease. The shared case wants to be an example: we will discuss the story of a 54 years old woman with extensive metastatic localizations in the skin that has obtained an important clinical response to therapy with sacituzumab govitecan, a conjugate antibody approved for the treatment of adult patients with metastatic triple negative breast cancer.
Insights
Advanced triple-negative breast cancer presents a poor prognosis. Sacituzumab govitecan offers encouraging results, demonstrating significant clinical response in a patient with metastatic triple-negative breast cancer.
Area of Science:
- Oncology
- Medical Research
- Pharmacology
Background:
- Advanced triple-negative breast cancer (TNBC) has a poor prognosis and limited treatment options.
- Conventional therapies often show poor response rates in TNBC patients.
- Targeted therapies and molecular research are improving treatment perspectives.
Observation:
- A case study of a 54-year-old woman with extensive skin metastases from TNBC.
- The patient received sacituzumab govitecan therapy.
- The patient experienced a significant clinical response to the treatment.
Findings:
- Sacituzumab govitecan demonstrated efficacy in treating metastatic triple-negative breast cancer.
- The antibody-drug conjugate showed a positive clinical outcome in a patient with extensive disease.
- This highlights the potential of targeted therapy in advanced TNBC.
Implications:
- Sacituzumab govitecan represents a promising therapeutic option for advanced TNBC.
- This case supports further investigation into targeted therapies for aggressive breast cancer subtypes.
- Advances in molecular research are crucial for developing effective treatments for challenging cancers.
More Related Videos
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
08:29Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014